PRINCETON, NJ -- (MARKET WIRE) -- November 28, 2006 -- China Biopharma, Inc. (OTCBB: CBPC), a biopharmaceutical company focused on developing and distributing human vaccine products in China, announced today that it has signed a letter of intent (LOI) with HYTE Research LLC, a New Jersey-based biotechnology research company. According to the agreement, the companies will jointly develop and commercialize Nano-Poly Enhancement technology for improving the effectiveness and reducing the side effects of human vaccines.
